Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

Claes-Göran Löfdahl, Theodore F Reiss, Jonathan A Leff, Elliot Israel, Michael J Noonan, Albert F Finn, Beth C Seidenberg, Thomas Capizzi, Sudeep Kundu, Philippe Godard

Abstract

Objective To determine the ability of montelukast, a leukotriene receptor antagonist, to allow tapering of inhaled corticosteroids in clinically stable asthmatic patients.

Design Double blind, randomised, placebo controlled, parallel group study. After a single blind placebo run in period, during which (at most) two inhaled corticosteroid dose decreases occurred, qualifying, clinically stable patients were allocated randomly to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks.

Setting 23 academic asthma centres in United States, Canada, and Europe.

Participants 226 clinically stable patients with chronic asthma receiving high doses of inhaled corticosteroids (113 randomised to montelukast and 113 to placebo).

Interventions Every 2 weeks, the inhaled corticosteroid dose was tapered, maintained, or increased (rescue) based on a standardised clinical score.

Main outcome measures Last tolerated dose of inhaled corticosteroids.

Results Compared with placebo, montelukast allowed significant (P = 0.046) reduction in the inhaled corticosteroid dose (montelukast 47% vs placebo 30%; least square mean difference 17.6%, 95% confidence interval 3.9 to 34.8). Fewer patients on montelukast (18 (16%) vs 34 (30%) placebo, P = 0.01) required discontinuation because of failed rescue.

Conclusions Montelukast reduces the need for inhaled corticosteroids among patients requiring moderate to high doses of corticosteroid to maintain asthma control.

Introduction

People with persistent asthma often require daily treatment to control symptoms, usually with inhaled corticosteroids. Recent publications have shown that in patients whose asthma is not completely controlled by inhaled corticosteroids, adding a second drug rather than increasing the dose of corticosteroid achieves better control. Leukotriene receptor antagonists have complementary effects to corticosteroids on inflammatory events in asthma, providing a basis for these additive clinical effects. Montelukast is a potent, specific, cysteinyl leukotriene receptor antagonist which, given daily, improves asthma control in adults and children, protects against exercise induced bronchoconstriction, and decreases sputum eosinophil counts. Subgroup analyses of previously reported clinical trials have suggested that montelukast has an additive effect with inhaled corticosteroids.

We performed a placebo controlled, double blind, randomised trial to investigate whether daily treatment with montelukast (10 mg) allowed reduction of inhaled corticosteroids while maintaining asthma control.

Participants and methods

Participants

We recruited 226 non-smoking adults with a clinical history of asthma for at least 1 year. Their forced expiratory volume in 1 second was at least 67% of predicted. Patients were treated with inhaled corticosteroids. Allocation was according to a computer generated allocation schedule with a blocking factor of 4. Three blocks were initially sent to each centre. Patients remained on their randomised treatment during the run in which was to achieve or approach the minimum required dose of inhaled corticosteroids. Allocation was according to a computer generated allocation schedule with a blocking factor of 4. Three blocks were initially sent to each centre.

The protocol was approved by the ethics review committees or institutional review boards of all participating centres. Written informed consent was obtained from all participants.

Study design

The study was conducted at 23 academic medical centres or large group practices in the United States, Canada, and Europe. We used a randomised, double blind, placebo controlled, parallel group design to investigate the effect of montelukast (10 mg tablet once daily at bedtime, irrespective of food) on the ability to taper the dose of inhaled corticosteroids over 12 weeks. Patients who met the inclusion criteria were randomised to receive montelukast (10 mg tablet) or matching placebo once daily at bedtime for up to 12 weeks. On average, 3.8 doses of inhaled corticosteroids were tapered over the treatment period. The protocol was approved by the ethics review committees or institutional review boards of all participating centres. Written informed consent was obtained from all participants.

University Hospital, Lund, Sweden
Claes-Göran Löfdahl, professor of respiratory medicine
Department of Pulmonary and Immunology, Merck Research Laboratories, Rahway, NJ 07065, USA
Theodore F Reiss, senior director
Jonathan A Leff, associate director
Beth C Seidenberg, vice president, clinical research
Department of Biostatistic and Research Data System, Merck Research Laboratories
Thomas Capizzi, senior director, clinical biostatistics
Sudeep Kundu, senior biostatistician
Elliot Israel, director, clinical research
continued over

BMJ 1999;319:87-90

extra

The members of the Montelukast Study Group are listed on the BMJ’s website

www.bmj.com
Criteria for tapering dose of inhaled corticosteroids: composite clinical score

| Before β agonist FEV₁ ≥ 90% of value at allocation | Yes = 1 point | No = 0 points |
| Daytime symptom score ≤ 120% of preallocation* baseline | Yes = 1 point | No = 0 points |
| β Agonist use ≤ 135% of preallocation* baseline | Yes = 1 point | No = 0 points |

Score

3 Points: patient stable = taper inhaled corticosteroid
2 Points: patient stable = maintain dose of inhaled corticosteroid
0 or 1 point: patient unstable = increase dose of inhaled corticosteroid

*Established 7-10 days before allocation visit to clinic

Table 1 Characteristics of patients before randomisation. Values are mean (SD) unless stated otherwise

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo</th>
<th>Montelukast</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>113</td>
<td>113</td>
</tr>
<tr>
<td>Mean (range) age (years)</td>
<td>41 (16-68)</td>
<td>40 (17-70)</td>
</tr>
<tr>
<td>No of men</td>
<td>61</td>
<td>47</td>
</tr>
<tr>
<td>Duration of asthma (years)</td>
<td>19 (14.0)</td>
<td>18 (13.3)</td>
</tr>
<tr>
<td>FEV₁ (% predicted)</td>
<td>82.3 (12.0)</td>
<td>84.8 (11.1)</td>
</tr>
<tr>
<td>Daytime symptom score</td>
<td>1.36 (0.8)</td>
<td>1.29 (0.7)</td>
</tr>
<tr>
<td>β Agonist use (puffs/day)</td>
<td>2.8 (2.6)</td>
<td>2.4 (2.2)</td>
</tr>
</tbody>
</table>

*Includes all patients randomly allocated in period two. One patient in the montelukast treatment group did not have any postallocation data available. †Daily average of four questions, 0-6 point scale. FEV₁ = forced expiratory volume in 1 second.

Results

Randomisation and withdrawals

Of the 226 patients (113 randomised to placebo, 113 to montelukast), one could not be included in the analysis (montelukast) because of insufficient postallocation data. A further 48 patients did not complete 12 weeks’ treatment: 31 in the placebo group (16 for “failed rescue,” nine for clinical adverse experiences, three for protocol deviations, and three withdrew consent) and 17 in the montelukast group (seven for “failed rescue,” four for clinical adverse experiences, four for protocol deviations, one withdrew consent, and one lost to follow up). The two treatment groups did not differ in baseline values (table 1).

The mean inhaled corticosteroid dose for the 226 allocated patients was reduced 37.3% before randomisation (tables 2 and 3). The postallocation doses of inhaled corticosteroids, daily symptoms, β agonist use, and forced expiratory volumes were comparable between treatment groups (tables 1 and 3). Compared with placebo, montelukast significantly (P = 0.046) reduced the last tolerated dose of inhaled corticosteroids. Mean percentage changes from preallocation baseline were 47% and 30% for the montelukast and placebo groups, respectively (least square mean difference 17.6%, 95% confidence interval 0.3 to 34.8; table 5). Tapering was consistent across all inhaled corticosteroids.

Forty five (40%) patients on montelukast and 33 (29%) on placebo tapered completely off inhaled corticosteroids. Seventy (62%) patients on montelukast compared with 57 (50%) on placebo had their dose tapered by 50% or more of the prerandomisation baseline; 31 (28%) on montelukast and 41 (36%) on placebo could not taper at all (P = 0.055).

Thirty four (30%) patients on placebo had failed rescues compared with 18 (16%) on montelukast (P = 0.01). In addition, time to failed rescue was better with montelukast compared with placebo (P = 0.042, log rank test).

No significant differences occurred between treatment groups in the change in spirometry measurements (% change in forced expiratory volume 2.7% montelukast v 5.4% placebo), asthma symptom score compared between treatment groups as the percentage change from preallocation baseline (to adequately summarise changes in corticosteroids of different potencies) with an analysis of variance model. This model was used to construct 95% confidence intervals for the least square mean values and differences of means. All statistical tests were two tailed, and a P value ≥ 0.05 was considered significant.

The number (percentage) of patients with failed rescue and tapering were prespecified as a secondary end point and were compared between treatment groups by the Cochran-Mantel-Haenszel test. The time to failed rescue was compared with a log rank test.

The study was designed with a sample size of 100 patients in each group to have 90% power to detect (α = 0.05), two tailed test a mean difference between the two treatment groups of about 30 percentage points in the percentage change from baseline in dose of inhaled corticosteroids.¹¹

References


(0.07 v 0.12), and β agonist use (0.29 v 0.36 puffs/day) at the last tolerated dose.

There were no significant differences in the frequency of clinical or laboratory adverse experiences between placebo and montelukast patients. Nine patients on placebo and four on montelukast stopped the trial because of adverse effects (worsening asthma for all montelukast patients).

**Discussion**

We found that, compared with placebo, montelukast (10 mg, administered once daily at bedtime) allowed reduction of moderate to high doses of inhaled corticosteroids while maintaining clinical stability in patients with chronic asthma. These data demonstrate that montelukast has an additive benefit to inhaled corticosteroids, although the study used a different design. Given the potential limitations of prolonged exposure high doses of inhaled corticosteroids, although the study used a different design. The similar in forced expiratory volume, symptoms, and use of β agonists supports similar disease severity in these patients. Furthermore, a lower inhaled corticosteroid dose at allocation might provide less opportunity for tapering in montelukast patients.

At allocation, patients appeared well matched. Although the inhaled corticosteroids dose was slightly lower in montelukast patients, the similarity in forced expiratory volume, symptoms, and use of β agonists supports similar disease severity in these patients. Furthermore, a lower inhaled corticosteroid dose at allocation might provide less opportunity for tapering in montelukast patients.

A second, important finding of this study was that the number of failed rescues was lower with montelukast than placebo. Patients taking montelukast were more likely to be successfully rescued after an episode of worsening asthma and therefore more likely to remain clinically stable.

Since the study was time based (12 weeks after randomisation) not event based, it had certain limitations.

**Key messages**

- Leukotriene receptor antagonists have complementary action to inhaled corticosteroids in asthma
- Many patients receive higher doses of inhaled corticosteroids than clinically required
- In this placebo controlled trial, montelukast allowed significant reduction of inhaled corticosteroid doses
- Fewer patients receiving montelukast had failed rescue than patients receiving placebo

In some patients, tapering (based on clinical stability) could have continued beyond 12 weeks; therefore, the true number of patients who could have stopped inhaled corticosteroids is unknown. Additionally, since patients were not followed beyond the 12 weeks we do not know how many required the reintroduction of inhaled corticosteroids to maintain clinical stability. A study with longer follow up would allow more complete understanding of the clinical importance of the effect of montelukast observed in this study.

Montelukast was generally well tolerated in this asthmatic population taking high doses of inhaled corticosteroids. Double blind, placebo controlled, clinical trials have confirmed the short term (≤3 month) safety profile in adults and children (ages 6-14). Additional long term clinical trials and real world clinical experience are necessary to understand the long term safety profile of leukotriene receptor antagonists.

In conclusion, our results suggest that leukotriene receptor antagonists such as montelukast may be useful for long term treatment of asthmatic patients requiring high doses of inhaled corticosteroids.

**Table 2** Mean (range) doses* of inhaled corticosteroids before study and before allocation

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Prestudy (µg/day)</th>
<th>Pre-allocation (µg/day)</th>
<th>Last tolerated (µg/day)</th>
<th>% reduction from allocation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo</td>
<td>1000 (500 to 1500)</td>
<td>714.3 (300 to 1500)</td>
<td>687.5 (300 to 1500)</td>
<td>12%</td>
</tr>
<tr>
<td>Montelukast</td>
<td>1165.0 (800 to 2000)</td>
<td>715.0 (400 to 1500)</td>
<td>687.5 (300 to 1500)</td>
<td>12%</td>
</tr>
</tbody>
</table>

*Dose actuated, not delivered at mouthpiece.

**Table 3** Mean (SD) changes in inhaled corticosteroid dose (µg/day) during study

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>1661 (670)</th>
<th>1079 (557)</th>
<th>727 (743)</th>
<th>30%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Montelukast</td>
<td>1588 (646)</td>
<td>916 (553)</td>
<td>520 (716)</td>
<td>47%</td>
</tr>
</tbody>
</table>

*P=0.046 compared with placebo.

In some patients, tapering (based on clinical stability) could have continued beyond 12 weeks; therefore, the true number of patients who could have stopped inhaled corticosteroids is unknown. Additionally, since patients were not followed beyond the 12 weeks we do not know how many required the reintroduction of inhaled corticosteroids to maintain clinical stability. A study with longer follow up would allow more complete understanding of the clinical importance of the effect of montelukast observed in this study.

Montelukast was generally well tolerated in this asthmatic population taking high doses of inhaled corticosteroids. Double blind, placebo controlled, clinical trials have confirmed the short term (≤3 month) safety profile in adults and children (ages 6-14). Additional long term clinical trials and real world clinical experience are necessary to understand the long term safety profile of leukotriene receptor antagonists.

In conclusion, our results suggest that leukotriene receptor antagonists such as montelukast may be useful for long term treatment of asthmatic patients requiring high doses of inhaled corticosteroids.

The members of the Montelukast Study Group are listed on the BMJ's website. We thank Ji Zhang for expert statistical advice and Lars-Olof Eriksson for study monitoring.

Contributors: The manuscript was written collaboratively by TFR, TFR, JAL, C-GL, EI, PG, and SK. TFR, TFR, JAL, BCS, SK, C-GL, and TC participated in the design of the clinical trial. C-GL, EI, MJN, AFF, and PG participated in data collection. SK and TC participated in the statistical planning and analysis. TFR is the study guarantor.

Funding: This study was supported by a grant from Merck Research Laboratories, Rahway, NJ.

Competing interests: C-GL is a member of a Merck advisory board, AFF owns shares of Merck stock and is a member of the Merck speakers bureau. MJN is a member of Merck speakers bureau and a member of a scientific council sponsored by Merck, and EI is a member of a scientific council sponsored by Merck.

What are leukotrienes and how do they work in asthma?

Acute asthma attacks are often triggered by allergens or exercise. Inflammatory molecules called leukotrienes are one of several substances which are released by mast cells during an asthma attack, and it is leukotrienes which are primarily responsible for the bronchoconstriction. In chronic, more severe cases of asthma, general bronchial hyperreactivity (or smooth muscle twitchiness) is largely caused by eosinophils, which are attracted into the bronchioles by leukotrienes (and other chemoattractants) and which themselves also produce leukotrienes. Thus leukotrienes seem to be critical both in triggering acute asthma attacks and in causing longer term hypersensitivity of the airways in chronic asthma.

Leukotrienes are derived from arachidonic acid, the precursor of prostaglandins. There are two families of leukotrienes. The first group acts primarily in conditions in which inflammation is dependent on neutrophils, such as cystic fibrosis, inflammatory bowel disease, and psoriasis. The second group (cysteinyl-leukotrienes) is concerned primarily with eosinophil and mast cell induced bronchoconstriction in asthma. They bind to highly selective receptors on bronchial smooth muscle and other airway tissue (Annals of Internal Medicine 1997;127:472-80).

Drugs have now been designed which can interfere with the activity of leukotrienes. Both leukotriene synthesis inhibitors and cysteinyl-leukotriene receptor antagonists have recently been shown to protect asthmatic patients against asthma attacks, but they are not useful as “rescue remedies” once an attack has already started. They act by preventing leukotriene release from mast cells and eosinophils or by blocking the specific leukotriene receptors on bronchial tissues, thus preventing bronchoconstriction, mucus secretion, and oedema.

These drugs also reduce the influx of eosinophils, thus limiting inflammatory damage in the airway. These oral, non-steroidal, anti-inflammatory drugs reduce the incidence of acute asthma attacks when taken regularly. Abi Berger, science editor, BMJ